Health ❯ Healthcare

Chronic Diseases

Diabetes Obesity Type 2 Diabetes Heart Disease Kidney Disease Cardiovascular Diseases Cardiovascular Health Hypertension Respiratory Diseases Cardiovascular Disease

New U.S. Cholesterol Guideline Shifts Prevention Earlier, Endorses PREVENT and Clear LDL Goals

Leaders signaled forthcoming updates based on trial evidence favoring more intensive LDL lowering.

Biomea Fusion Reports Positive 52-Week Phase II Results for Icovamenib in Diabetes

World Glaucoma Day Spurs Free Screenings as Data Show Many Unaware of the Risk

Viking Therapeutics Pushes VK2735 Through Pivotal Trials as Next Enrollment Milestone Nears

Norway’s Crown Princess Mette-Marit Prepared for Lung-Transplant Assessment After Health Setback

Most Weight Lost on GLP-1 Drugs Returns After Stopping, New Analysis Finds

GLP-1 Drugs Tied to Lower Addiction Risk and Harms in Large VA Study

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Merck and Mayo Clinic Launch AI Drug Discovery Collaboration Using Platform_Orchestrate

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

Beta Bionics Beats Q4 Estimates, Sets 2026 Guidance With Pharmacy-Channel Targets

Germany’s Alcohol-Related Hospitalizations Hit Decade Low in 2024, Down 29% Since 2014

Tânia Maria Begins Lung Evaluation as Oscars Trip Awaits Clearance

Lancet Review Urges India to Rethink HbA1c-Only Diabetes Testing

Time-Restricted Eating Cuts Crohn’s Disease Activity 40% in 12-Week Trial

Major Lancet Analysis Finds Most Statin Label Side Effects Not Caused by the Drugs

GLP-1 Era Hits the Mainstream With Super Bowl Ads as Costs Rise and Care Shifts to Maintenance

Kidney Drug Finerenone Shows Early Promise in Restoring Egg Development in Early Menopause

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection